Immutep Limited (IMMP)
IMMP trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC filing XBRL, 20-F (ifrs-full:Revenue), fiscal year ended 2026-06-30, https://www.sec.gov/Archives/edgar/data/1506184/000119312526429413/0001193125-26-429413-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), fiscal year ended 2026-06-30. Converted from AUD at 1.4738 per USD (today's ECB or Federal Reserve reference rate).
Profile
| Field | Value |
|---|---|
| Ticker | IMMP on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Australia |
| IPO year | Not reported by the screener |
| SEC CIK | 0001506184 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Australia |
Financials · 2026
| Line | Value |
|---|---|
| Revenue | $16.4M |
| Net income | -$53.8M |
| Operating income | Not in SEC XBRL data |
| Net margin | -328.1% |
| Operating margin | Operating income not reported |
| Revenue growth | +133.9% |
| Cash | $43.2M |
| Total assets | $56.5M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 1.5× |
Reported in AUD; shown in US dollars.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-10-23 |
| Cash and burn | 63.7M AUD cash; operating cash flow -13.9M AUD a quarter. | Report 2026-06-30 |
| Shares outstanding | 7,368,607 (2026-06-30); 7,301,948 a year earlier; 5,936,531 three years earlier. 1y figure adjusted for splits (1-for-20 overall); 3y figure adjusted for splits (1-for-20 overall). | Cover page 2026-06-30 |
| Reverse splits, 3 years | 1; latest 1-for-20 on 2026-09-28 | Source 2026-09-28 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers, Sydney, Australia | PCAOB Form AP 2026-11-05 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $0, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2026 2026-06-30 | 24.2M AUD | -79.3M AUD | -55.5M AUD | 63.7M AUD | No debt tags | 24.2M AUD | 20-F 2026-10-23 |
| FY 2025 2025-06-30 | 10.3M AUD | -61.4M AUD | -62.0M AUD | 67.4M AUD | No debt tags | 10.3M AUD | 20-F 2025-10-24 |
| FY 2024 2024-06-30 | 7.8M AUD | -42.7M AUD | -34.8M AUD | 161.8M AUD | No debt tags | 7.8M AUD | 20-F 2025-10-24 |
| FY 2023 2023-06-30 | 5.2M AUD | -39.9M AUD | -35.4M AUD | 123.4M AUD | No debt tags | 5.2M AUD | 20-F 2025-10-24 |
| FY 2022 2022-06-30 | 6.8M AUD | -32.2M AUD | -30.2M AUD | 80.0M AUD | No debt tags | 6.8M AUD | 20-F 2024-10-22 |
| FY 2021 2021-06-30 | 4.0M AUD | -29.9M AUD | -17.6M AUD | 60.6M AUD | No debt tags | 4.0M AUD | 20-F 2023-10-24 |
| FY 2020 2020-06-30 | 16.5M AUD | -13.5M AUD | -10.8M AUD | 26.3M AUD | No debt tags | 16.5M AUD | 20-F 2022-10-31 |
| FY 2019 2019-06-30 | 7.5M AUD | -18.3M AUD | -15.3M AUD | 16.6M AUD | No debt tags | 7.5M AUD | 20-F 2021-10-25 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months). Amounts in AUD.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | F-3 | 2023-04-28 |
| Latest annual report | 20-F | 2026-10-23 |
| Latest quarterly / interim | 6-K | 2026-11-10 |
Source: SEC EDGAR submissions feed, 740 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +4.2% |
| 1 month | -2.5% |
| 3 months | -56.5% |
| Year to date | +21.7% |
| 1 year | +89.1% |
| From 52-week high | -94.5% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CRVO | CervoMed Inc. | $1.67 | -1.18% | $25.3M |
| ABVC | ABVC BioPharma Inc. | $0.9400 | +3.30% | $25.4M |
| EDSA | Edesa Biotech Inc. Common Shares | $1.89 | -2.58% | $25.5M |
| LITS | Lite Strategy Inc. | $0.8565 | +1.16% | $25.6M |
| ACET | Adicet Bio Inc. | $2.75 | -1.08% | $25.7M |
| IXHL | Incannex Healthcare Inc. | $1.93 | -2.03% | $24.2M |
| BYSI | BeyondSpring Inc. | $0.5788 | -3.73% | $23.8M |
| MIRA | MIRA Pharmaceuticals Inc. | $0.6310 | -4.38% | $26.5M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier